In-vivo proof of concept in malignant melanoma
(Thomson Reuters ONE) -
LU Bio portfolio company Cantargia has achieved in-vivo proof of concept
targeting IL1RAP expressing human tumor. The concept of targeting IL1RAP has
with these findings been further validated. The results show highly significant
inhibition of tumor growth in a transplanted in-vivo model of human malignant
melanoma, this as a result of the treatment with a Cantariga-developed anti-
IL1RAP monoclonal antibody.
LU Bio has in total invested SEK 6,8 million in Cantargia and holds a position
of 53 %, others being the founders.
The company has previously presented significant anti malignant effects in an
ex-vivo model of human leukemia. The project is based on the original discovery
of IL1RAP as a unique receptor on leukemic stem cells in patients with chronic
myeloid leukemia. The IL1RAP receptor has also been shown to be up-regulated on
stem cells of AML and ALL.
"These results validate the concept in-vivo as well as represent an additional
therapeutic target for an antibody based therapy against IL1RAP" says Agneta
Svedberg, CEO of Cantargia.
"Already with the conceptually new therapy for hematologic malignancies,
Cantargia appeared highly valuable" says Thomas Andersson, CEO of LU Bioscience
AB. "The new promise of a therapy also against solid tumors is very attractive."
For more information, please contact:
Thomas Andersson, CEO LU Bio, thomas(at)lubio.se, telephone +46 70 287 00 15
Agneta Svedberg, CEO Cantargia, agneta.svedberg(at)cantargia.com, +46 (0)
705 14 11 63
About Cantargia AB
Cantargia is developing a conceptually new cancer therapy, based on the original
discovery that certain leukemia stem cells express a specific cell-surface
receptor, whereas corresponding normal hematopoietic stem cells do not express
this receptor. This receptor is used as a target for development of a new
antibody based therapy. Cantargia uses this receptor, the Interleukin-1 receptor
accessory protein (IL1RAP), as the target for development of a novel antibody-
based therapy for CML. For more information on Cantargia please visit
www.cantargia.com.
About LU Bioscience AB
Lund University Bioscience AB (LU Bio) was established to help satisfy the need
to transform high-end research results and innovations into attractive business
propositions through supporting researchers. LU Bio is a commercial early-stage
investor who provides both capital and industrial development expertise to
enable a fast and efficient development of bioscience inventions. For more
information on Cantargia please visitwww.lubio.se
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: LU Bioscience via Thomson Reuters ONE
[HUG#1584123]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="S&P Capital IQ Initiates Coverage on Canamex Resources Corp in Standard & Poor’s Factual Stock Reports
Datum: 09.02.2012 - 11:57 Uhr
Sprache: Deutsch
News-ID 112950
Anzahl Zeichen: 3376
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 233 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"In-vivo proof of concept in malignant melanoma"
steht unter der journalistisch-redaktionellen Verantwortung von
LU Bioscience (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
